U.S. markets closed

Tauriga Sciences, Inc. (TAUG)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0690+0.0065 (+10.40%)
At close: 3:58PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0625
Open0.0610
BidN/A x N/A
AskN/A x N/A
Day's Range0.0610 - 0.0700
52 Week Range0.0207 - 0.1985
Volume649,235
Avg. Volume1,007,489
Market Cap17.736M
Beta (5Y Monthly)2.02
PE Ratio (TTM)N/A
EPS (TTM)-0.0140
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Tauriga Sciences Inc. Introduces Innovative New Product Offering, Exclusively Available on Company’s E-Commerce Website - Super Deluxe Rainbow Pack @ $136.99 Each
    GlobeNewswire

    Tauriga Sciences Inc. Introduces Innovative New Product Offering, Exclusively Available on Company’s E-Commerce Website - Super Deluxe Rainbow Pack @ $136.99 Each

    June 1st PR Image Super Deluxe Rainbow Pack Unit NEW YORK, NY, June 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today introduced the Company’s Super Deluxe Rainbow Pack (“Super Pack” or “Pack”), which is comprised of 1 Blister Pack (each of the 9 Tauri-Gum SKUs). Each Pack will also include a 10thBlister Pack “Mystery Flavor” and a limited Edition (intricately designed) ded

  • Tauriga Sciences Inc. Prepares for Major Upcoming Product Launch and Introduces Expanded Tauri-Gummies™ Product Line
    GlobeNewswire

    Tauriga Sciences Inc. Prepares for Major Upcoming Product Launch and Introduces Expanded Tauri-Gummies™ Product Line

    May 27th PR Image Enhanced Tauri-Gum™Product Line NEW YORK, NY, May 27, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, today announced its preparations for its major upcoming product launch as well as the expansion of its Tauri-Gummies™ product line. The Company has worked with great diligence to be Innovative, with respect to the enhancement of its products and product lines. The Company is confident in its ability to gain market share and is continuing to increase its salesforce and its visibility to a broad array of potential new customers. The Company is making final preparations for the upcoming launch of its enhanced Tauri-Gum™ product line (its flagship product line). Expected to occur during early June 2021, this product launch will include: 5 SKUs of 25mg CBD & CBG infused chewing gum, 1 SKU of 10mg Delta 8 THC infused chewing gum, 3 SKUs of Cannabinoid free chewing gum (Vitamin C + Zinc, Caffeine, Vitamin D3) and 2 SKUs pursuant to License Agreement (to be disclosed within the near term). The Company is also planning a June 2021 launch of its expanded and enhanced Tauri-Gummies™ product line. This product launch will include: Original 25mg CBD infused gum drops (re-formulated without artificial colors), 25mg Delta 8 THC infused Blue Raspberry gummies, and 25mg Delta 8 THC + Melatonin + infused Wild Blueberry gummies. Additionally, the Company is pleased to announce its plans to open its first retail location. Once finalized, the Company will notify shareholders about the specific details. Due to the Company’s strong balance sheet and liquidity, the Company has the flexibility to pursue multiple opportunities to grow revenue, brand exposure, and material partnerships. In other news, the Company continues to realize important progress, with respect to its Pharmaceutical development efforts. The Company has assembled an experienced and highly qualified clinical development team and expects to provide update(s) to shareholders within the near term. ABOUT TAURIGA SCIENCES INC. Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts. The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York. DISCLAIMER -- Forward-Looking Statements This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements. Contact: Tauriga Sciences, Inc. 4 Nancy Court, Suite 4 Wappingers Falls, NY 12590 Chief Executive Officer Mr. Seth M. Shaw Email: sshaw@tauriga.com cell # (917) 796 9926 Company Instagram: @taurigum Personal Instagram: @sethsms47 Twitter: @SethMShaw Corp. Website: www.tauriga.com E-Commerce Website: www.taurigum.com Attachment May 27th PR Image

  • Tauriga Sciences Inc. Increases Size of Initial Production Run for its Delta 8 THC Infused Tauri-Gum Version
    GlobeNewswire

    Tauriga Sciences Inc. Increases Size of Initial Production Run for its Delta 8 THC Infused Tauri-Gum Version

    04_20 PR Image Delta 8 THC Tauri-Gum™ Blister Pack Sleeve This Initial Production Run has Been Doubled, Due to Strong Indications of Demand & Pre-Orders NEW YORK, NY, April 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire-- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences company, with a proprietary line of CBD & CBG infused Supplement chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant, Cherry Lime Rickey, Golden Raspberry, Evergreen Mint), additional product offerings, as well as an ongoing Pharmaceutical Development initiative, today announced that it has doubled the initial production run total(s) for its Delta 8 Tetrahydrocannabinol (“Delta 8 THC”) infused version of Tauri-Gum™ (9thoverall product line SKU). This Tauri-Gum™ product version is infused with 10mg of Delta 8 THC (per each piece of chewing gum) and is manufactured in Evergreen Mint flavor – MSRP per Blister Pack is $18.99. The Company is experiencing strong levels of performance and growth in its retail business. The Company has already generated record monthly sales (by a substantial margin), for the month of April 2021 (in just 20 days of this month). Driving the record performance in its retail business are the following factors: continued strength in E-Commerce business segment, Pre-Orders for its enhanced 25mg CBD/CBG infused versions of Tauri-Gum™, and Pre-Orders for its Delta 8 THC infused version of Tauri-Gum™. The Company’s previous monthly sales record of approximately $47,000, was established during July 2020. Lastly, the Company continues to realize important and material progress, with respect to its ongoing Pharmaceutical Development initiative. This initiative refers to the Company’s ongoing development of its proposed, Cannabinoid based, Pharmaceutical grade “Anti-Nausea” chewing gum, targeting nausea that emanates from ongoing chemotherapy treatment. The Company expects to issue additional update(s) to shareholders within the near term. ABOUT TAURIGA SCIENCES INC. Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts. The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York. DISCLAIMER -- Forward-Looking Statements This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements. Contact: Tauriga Sciences, Inc. 4 Nancy Court, Suite 4 Wappingers Falls, NY 12590 Chief Executive Officer Mr. Seth M. Shaw Email: sshaw@tauriga.com cell # (917) 796 9926 Company Instagram: @taurigum Personal Instagram: @sethsms47 Twitter: @SethMShaw Corp. Website: www.tauriga.com E-Commerce Website: www.taurigum.com Attachment 04_20 PR Image